Viking Therapeutics plans USD 200 million convertible senior notes offering due 2032

VKTX•2026-09-23

Use of proceeds

Proceeds are earmarked for the development and commercialization of VK2735, advancement of VK3019, working capital, and general corporate purposes.

Convertible notes offering

Viking Therapeutics launched a public offering of USD 200 million convertible senior notes due 2032.

Underwriters hold a 30-day option to buy up to an additional USD 30 million of the notes for over-allotments.

The notes are expected to mature on Oct. 15, 2032, will be senior unsecured, and will pay interest semi-annually. Conversion may be settled in cash, shares, or both.

The company said redemption will be allowed from Oct. 22, 2029 if the shares trade above 130% of the conversion price for a specified period.

Viking Therapeutics plans USD 200 million convertible senior notes offering due 2032

Use of proceeds

Convertible notes offering

Related News

Hinge Health President James Pursley disposes of common shares worth $3.08 million

BlackRock Canada sets iShares Premium Money Market ETF September cash distribution at $0.093 per unit

Oracle Expands Digital Assets Data Nexus To Help Banks Operationalize Digital Money

Five Below director Scott M. Settersten files initial beneficial ownership statement

Mercury Systems EVP, CLO and corporate secretary Stuart Kupinsky sells 1,000 shares for $86,520